You started GLP-1 expecting the same drop everyone else describes. The first month worked. Then the scale stopped moving, or worse, started creeping back. Here is exactly why it happens and what to do about it.
🔑 Key Takeaways
- The most common reason people stop losing weight on GLP-1 is not the drug, it is metabolic adaptation: as you lose fat, your body burns 200 to 400 fewer calories per day at the same dose.
- A "plateau" of 2 to 3 weeks is normal and not a plateau. A real plateau is 8 to 12 weeks of weight stability with no downward trend.
- Increasing your dose is not always the answer. Common reasons for a stall fixable without a dose increase: under-eating protein, over-restricting calories then rebound eating, alcohol, sleep debt, water retention masking fat loss, muscle gain.
- If you do need to increase dose, the standard protocol is a single step up (0.25 to 0.5 to 1.0 to 1.7 to 2.4 mg for semaglutide; 2.5 to 5.0 to 7.5 to 10 to 12.5 to 15 mg for tirzepatide) every 4 weeks, only after you have given the current dose at least 4 to 8 weeks.
- Maintenance dosing is real and often dropped one or two steps below your highest titration dose. Many people maintain their loss long-term on 1.0 mg semaglutide or 5 to 7.5 mg tirzepatide.
- Stopping GLP-1 cold is the fastest way to regain weight. A taper, a maintenance dose, or a structured transition is what the long-term data supports.
- Restarting after more than 12 weeks off requires retitration from a low dose. Going straight back to your old dose is the most common cause of severe nausea and rebound nausea-induced weight loss that does not stick.
- Not everyone needs a dose increase. Some people respond to lower doses for longer than the FDA label suggests, and that is a feature, not a failure.
This page is the playbook for everything that goes wrong on GLP-1 weight loss after the first 6 months. Why the scale stops moving, when to increase your dose and when not to, what a real maintenance dose looks like, how to take a break safely, and how to restart without re-living the first-month nausea.
Why You're Not Losing Weight on GLP-1
The drug is rarely the problem.
About 85% of people on a long-term weight loss program hit a plateau. Most do it around the 9 to 12 month mark. The reason is not that GLP-1 stopped working. It is that your body is now smaller, more efficient, and pulling more counter-regulatory levers. Going through these in order is faster than guessing.
1. Metabolic adaptation
The biggest one. After losing 10% of your body weight, your basal metabolic rate drops by 10 to 25%, which translates to 200 to 400 fewer calories burned per day at rest. Thyroid hormone (T3) drops slightly, sympathetic nervous system tone drops, and your body becomes a more fuel-efficient version of itself. This is not a bug. It is what kept your ancestors alive in food-scarce environments. The fix is not eating less, it is eating better while preserving muscle and accepting a slower trajectory.
2. Leptin and ghrelin shift
As fat cells shrink, leptin (the satiety hormone) drops, and ghrelin (the hunger hormone) rises. GLP-1 partly suppresses ghrelin signaling, but as the gap widens, the appetite-suppressing effect of the drug feels weaker even at the same dose. Most people experience this as "I am getting hungry between meals again."
3. You are eating more than you think
The single most common reason people stop losing weight is calorie creep. As nausea fades, portion sizes drift up. As food enjoyment returns, the steady appetite suppression of weeks 4 through 12 starts to feel less restrictive. A 200 to 300 calorie daily creep is enough to halt loss completely.
4. Protein is too low
Most people eating in a calorie deficit on GLP-1 are under-eating protein. Below 0.6 g per pound of goal body weight, lean mass loss accelerates, the metabolic adaptation gets steeper, and the scale weight loss looks fine but the body composition is getting worse. Aim for 0.6 to 1.0 g per pound of goal body weight, daily.
5. Alcohol
Three things happen when you drink on GLP-1: alcohol calories add up fast, the alcohol blunts the appetite-suppression effect for 24 to 48 hours, and alcohol disrupts the sleep that maintains hormonal balance. Two drinks twice a week is enough to stall progress.
6. Sleep debt
Less than 6 hours of sleep raises ghrelin by roughly 15% and drops leptin by roughly 15%. The same dose of GLP-1 does not feel as effective when you are sleep-deprived because the hormonal floor it has to fight against is higher.
7. Water retention is masking fat loss
Stress, sodium, hormonal cycles, and travel all cause water retention that can hide 2 to 4 weeks of fat loss. If your weight has been stable for 2 to 3 weeks, take measurements (waist, hip, thigh) and check them against the scale. If measurements are dropping while the scale is not, you are still losing fat. Wait it out.
8. You gained muscle
If you started strength training in the same window, the scale can stay flat or rise while body composition improves. Compare a body composition measurement (DEXA, smart scale, even calipers) to the scale. Muscle gain on a calorie deficit is rare but possible early in a training career.
9. Real metabolic plateau
If you have ruled out all the above and you are still stuck after 8 to 12 weeks at a fixed protocol, you have a real plateau. That is the point at which you consider a dose adjustment, a refeed week, an exercise change, or a scheduled break. Not before.
The GLP-1 Plateau: When It Happens and How Long It Lasts
A "plateau" of 2 to 3 weeks is not a plateau.
The body weight chart of every successful GLP-1 user has dozens of these flat 2 to 3 week stretches. The pattern is real loss, then a flat period of water shifts and metabolic catch-up, then more loss. Calling these plateaus and changing your protocol every time leads to chaotic dosing and worse outcomes than holding steady.
A real plateau has three characteristics:
- Duration: 8 to 12 weeks of stability, not 2 to 3
- Trend: No downward trajectory in body composition either (waist, measurements, body fat % all flat)
- Adherence: Your dose, food intake, and activity are consistent (so the plateau is not just inconsistency in disguise)
When all three are true, the plateau is biological, and that is when the dose adjustment, lifestyle change, or break decisions actually matter.
When to Increase Your GLP-1 Dose
The standard protocol is "one step every 4 weeks", but the honest answer is more nuanced.
The semaglutide titration ladder is 0.25 to 0.5 to 1.0 to 1.7 to 2.4 mg, weekly. The tirzepatide ladder is 2.5 to 5.0 to 7.5 to 10 to 12.5 to 15 mg, weekly. The "every 4 weeks" rule is the manufacturer-recommended pace and the dose at which insurance approvals are typically tied. The clinical reality is that some people respond fully at lower doses and never need to climb the ladder.
| Sign | What it means | What to do |
|---|---|---|
| Losing weight steadily, no major side effects | Current dose is working | Stay where you are. Do not increase just to follow the schedule. |
| Hunger creeping back, portions growing | Possible appetite escape | Increase one step after at least 4 to 8 weeks at current dose |
| Plateau (8 to 12 weeks, no body comp change) | Time to change something | Increase one step OR adjust diet/exercise first if those are off |
| Severe nausea, can't eat | Dose is too high | Drop back one step. Do not increase further. |
| Mild GI side effects, manageable | Body is adjusting | Stay 2 to 4 more weeks before any changes |
| BMI is below 27 and weight loss has been substantial | You are near goal | Stop climbing. Plan for maintenance. |
Why "every 4 weeks automatically" is wrong
The ladder is a maximum titration speed, not a target. If you are losing 1 to 2 lbs per week comfortably at 1.0 mg semaglutide, you do not need 1.7 mg, and increasing brings nausea, more aggressive appetite suppression that often backfires into rebound eating, and unnecessary cost. The phrase clinicians use is "titrate to effect, not to schedule".
GLP-1 Maintenance Dose: How Much and How Long
Maintenance is the part most people get wrong.
The fundamental insight from the long-term GLP-1 data, including STEP 4 and SURMOUNT-3, is that stopping the drug after reaching goal weight causes most people to regain about two-thirds of what they lost within a year. The question is not "do I stay on?" but "what is the lowest dose that holds my weight stable?"
| Drug | Highest titration dose | Common maintenance dose | Lowest reported maintenance |
|---|---|---|---|
| Semaglutide (Wegovy) | 2.4 mg weekly | 1.0 to 1.7 mg weekly | 0.25 to 0.5 mg weekly |
| Tirzepatide (Zepbound) | 15 mg weekly | 5 to 10 mg weekly | 2.5 mg weekly |
| Retatrutide (R-30) | 12 mg weekly (trial) | 4 to 8 mg weekly (extrapolated) | Not yet established |
How to drop down to a maintenance dose
- Reach a stable weight at your titration dose for at least 8 to 12 weeks. "Stable" means within 3 to 5% of your lowest weight without trending up.
- Drop one step down (e.g., 2.4 to 1.7 mg semaglutide).
- Hold for 8 to 12 weeks and watch the scale. If you are stable, the new dose is working as maintenance.
- If weight starts climbing by 3% or more, go back up one step. That is your maintenance floor.
- If weight stays stable, you can try dropping another step in another 8 to 12 weeks.
The savings are real: dropping from 2.4 mg to 1.0 mg semaglutide cuts your monthly drug cost by 50 to 60%. For people paying out of pocket or with high copays, this is the difference between sustainable long-term use and quitting.
Restarting GLP-1 After a Break
The mistake most people make is going straight back to the dose they stopped at.
GLP-1 receptors downregulate when the drug is gone. Going back to a high dose after weeks off triggers severe nausea, vomiting, and often a temporary "dose-induced weight loss" that does not stick because the user just abandons the drug again from the side effects. The protocol below is the one most weight-management clinics now use.
| Time off | Restart strategy | Notes |
|---|---|---|
| Less than 2 weeks | Resume previous dose | Receptors are still adapted. No retitration needed. |
| 2 to 12 weeks | Drop one step below your previous dose | e.g., were on 1.7 mg semaglutide, restart at 1.0 mg |
| 3 to 6 months | Drop two steps below or restart from initial titration | Most need to retitrate. Plan 8 to 12 weeks to climb back. |
| 6+ months | Restart from the beginning | 0.25 mg semaglutide or 2.5 mg tirzepatide. Full titration. |
Why people take breaks in the first place
- Supply shortages (Mounjaro and Wegovy were both supply-constrained for stretches in 2023 to 2025)
- Cost gaps (insurance coverage changes, prior auth denials, pharmacy backorders)
- Pregnancy planning (washout periods of 2 months for semaglutide, 1 month for tirzepatide)
- Side effect resets (taking a few weeks off to reset GI tolerance)
- Travel or work disruption (cold-chain issues, missed shipments)
- Wanting to test off-drug stability (often a mistake; most regain)
What If You Are Just Not Responding At All?
About 10 to 15% of people are non-responders or low-responders to GLP-1.
The clinical definition of a non-responder is failing to lose at least 5% of body weight over 12 weeks at a therapeutic dose with good adherence. If that describes you, the issue is rarely "more semaglutide". The next steps are usually:
- Switch from semaglutide to tirzepatide (the dual GLP-1/GIP agonist works for some semaglutide non-responders)
- Switch from tirzepatide to retatrutide (the triple agonist with up to 24% weight loss in Phase 3)
- Look for an underlying issue (untreated hypothyroidism, sleep apnea, Cushing's, PCOS, certain medications like SSRIs and antipsychotics that drive weight gain)
- Re-examine adherence (proper injection technique, consistent timing, full dose absorption)
For the broader picture on switching drugs, see our guide to switching from semaglutide to tirzepatide and our retatrutide vs tirzepatide comparison.
Frequently Asked Questions
Medical disclaimer. This article is informational only and does not replace individualized medical advice. Dose adjustments, maintenance protocols, and decisions about restarting or stopping GLP-1 medications should be made with the prescribing clinician who knows your full medical history. The data on long-term GLP-1 use is still developing, and individual responses vary widely.